Placebo + Seralutinib
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Dec 28, 2023 → Dec 22, 2025
NCT ID
NCT05934526About Placebo + Seralutinib
Placebo + Seralutinib is a phase 3 stage product being developed by Gossamer Bio for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05934526. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07181382 | Phase 3 | Active |
| NCT05934526 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension